Alvotech Announces European Launch of Gobivaz® (golimumab)

Alvotech has announced the European launch of Gobivaz® (golimumab), their biosimilar to Simponi® (golimumab), also known as AVT05. This marks the first marketed biosimilar to Simponi globally. The drug is being commercialized in Europe by Alvotech's partner, Advanz Pharma. The launch in the United Kingdom is supported by a National Health Service (NHS) England tender award, facilitating adoption within NHS services for immune-mediated inflammatory diseases. Alvotech expects availability across other European Economic Area (EEA) markets to progress according to national pricing and reimbursement processes. The company highlights that Gobivaz is an important treatment option for patients and aims to expand access to high-quality biologic medicines. The approval of Gobivaz was based on comprehensive studies demonstrating its biosimilarity to the reference product. Gobivaz is available in the same presentations and dosage forms as Simponi and is manufactured at Alvotech's facility in Iceland. Alvotech's pipeline includes nine other biosimilar candidates targeting various diseases.